DNAL1 Antibody

What is DNAL1 and what is its biological function?

DNAL1 (Dynein Axonemal Light Chain 1) is a component of the multisubunit axonemal ATPase complex that generates force for cilia motility and governs beat frequency. Specifically, it functions as part of the outer dynein arm (ODA) complex. DNAL1 serves a critical regulatory function by tethering the outer arm dynein heavy chain (DNAH5) to microtubules within the axoneme, thereby participating in the mechanosensory feedback mechanism that controls ODA activity. This protein directly interacts with tubulin and is essential for normal ciliary function in airways and for the nodal flow that determines left-right asymmetry during development . DNAL1 contains a leucine-rich-repeat (LRR) consensus domain that plays a crucial role in protein-protein interactions within the dynein complex . In humans, dynein is composed of heavy chains (~500 kD), intermediate chains (70-125 kD), and several light chains (15-30 kD), with DNAL1 falling into this last category .

How is DNAL1 involved in disease pathogenesis?

DNAL1 has been identified as a potential candidate gene for Primary Ciliary Dyskinesia (PCD), a genetically heterogeneous disorder characterized by chronic infections of the upper and lower airways, randomization of left-right body symmetry, and reduced fertility . Mutations in DNAL1 can significantly affect its binding capacity to both dynein heavy chain and tubulin, reducing these interactions by approximately 80% in experimental models . Additionally, certain mutations lead to protein instability, with mutated DNAL1 showing a 94% reduction after 6 hours compared to only 30% reduction in wild-type protein under the same conditions . Interestingly, DNAL1 has also been identified as an HIV dependency factor (HDF), suggesting potential importance as a drug target in HIV treatment strategies .

What is the molecular structure and characterization of DNAL1?

DNAL1 has a calculated molecular weight of 21,533 Da, though it typically appears at approximately 68 kDa on Western blots, likely due to post-translational modifications or complex formation . The protein contains a highly conserved leucine-rich-repeat (LRR) consensus domain, with critical residues like Asn150 showing complete conservation across species . This residue is specifically located between the β10 and α7 folds of the sixth LRR domain, highlighting its structural importance . At least two isoforms of DNAL1 have been identified, though functional differences between these variants require further investigation .

What criteria should be considered when selecting a DNAL1 antibody for research?

When selecting a DNAL1 antibody, researchers should evaluate several critical parameters:

• Species reactivity: Verify compatibility with your experimental model. Available antibodies typically react with human, mouse, and rat DNAL1 .

• Clonality and host: Consider whether polyclonal (offering multiple epitope recognition but potential batch-to-batch variation) or monoclonal (higher specificity for a single epitope) antibodies are more appropriate. Common DNAL1 antibodies are rabbit polyclonal IgG .

• Epitope location: Understand the target region of the antibody. For example, some antibodies are raised against a 17-amino acid synthetic peptide from near the carboxy terminus of human DNAL1 .

• Validated applications: Confirm that the antibody has been validated for your specific application (Western blot, immunocytochemistry, immunofluorescence, ELISA). Documented performance in relevant experimental contexts is essential for reliable results .

• Cross-reactivity: Review potential cross-reactivity with other proteins, especially other dynein family members. Some antibodies may detect multiple isoforms of the target protein .

How should DNAL1 antibody validation be performed for experimental applications?

Rigorous validation of DNAL1 antibodies should include:

• Western blot validation: Confirm expected molecular weight (observed at approximately 68 kDa despite a calculated weight of 21.5 kDa) . Run proteins from relevant tissues expressing DNAL1 (e.g., ciliated tissues) alongside negative controls.

• Immunocytochemistry controls: Perform parallel staining in tissues with high DNAL1 expression (respiratory epithelium, testes) alongside low-expression tissues. Include antibody concentration gradients (1-20 μg/mL) to determine optimal working dilutions .

• Peptide competition assay: Validate specificity by pre-absorbing the antibody with the immunizing peptide, which should substantially reduce or eliminate specific staining.

• Cross-species validation: If working with non-human models, validate antibody performance specifically in your experimental species, as reactivity may vary despite predicted cross-reactivity .

• Knockout/knockdown controls: When available, utilize DNAL1-deficient samples as negative controls to conclusively confirm antibody specificity.

What are the optimal storage and handling conditions for DNAL1 antibodies?

DNAL1 antibodies require specific storage and handling conditions to maintain functionality:

• Temperature conditions: Store at 4°C for short-term use (up to three months) or at -20°C for long-term storage (stable for up to one year) .

• Freeze-thaw cycles: Avoid repeated freeze-thaw cycles which significantly degrade antibody performance. Aliquot upon receiving to minimize freeze-thaw events .

• Buffer composition: Many commercial DNAL1 antibodies are supplied in PBS containing 0.02% sodium azide as a preservative .

• Temperature extremes: Do not expose antibodies to prolonged high temperatures during shipping or laboratory handling .

• Working dilution preparation: When preparing working dilutions, use fresh buffer (typically PBS with 1% BSA) and prepare only the amount needed for immediate use.

What are the recommended protocols for using DNAL1 antibody in Western blot analysis?

For optimal Western blot detection of DNAL1:

• Sample preparation: Extract proteins from cells/tissues of interest using standard lysis buffers containing protease inhibitors. For ciliated tissues, specialized extraction methods for axonemal proteins may improve detection.

• Loading and separation: Load 20-50 μg of total protein per lane. Use 10-12% SDS-PAGE gels for optimal separation of DNAL1 (observed at ~68 kDa) .

• Transfer and blocking: After electrophoresis, transfer proteins to a PVDF or nitrocellulose membrane. Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute DNAL1 antibody to 1-2 μg/mL in blocking buffer and incubate overnight at 4°C .

• Detection and visualization: After washing, incubate with appropriate HRP-conjugated secondary antibody and develop using chemiluminescence. Expected molecular weight is approximately 68 kDa despite a calculated weight of 21.5 kDa .

• Controls: Include positive controls (such as 3T3 cell lysate) where DNAL1 expression has been confirmed .

How can DNAL1 antibody be effectively used in immunocytochemistry and immunofluorescence?

For immunocytochemistry and immunofluorescence applications:

• Cell/tissue preparation: Fix cells or tissue sections with 4% paraformaldehyde for 15-20 minutes at room temperature. For tissues, perform antigen retrieval if necessary.

• Permeabilization: Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes at room temperature.

• Blocking: Block non-specific binding with 5-10% normal serum (matched to secondary antibody host) in PBS for 1 hour.

• Primary antibody application: Apply DNAL1 antibody at 2.5 μg/mL for immunocytochemistry or 20 μg/mL for immunofluorescence techniques .

• Co-staining considerations: When performing co-localization studies, consider counter-staining with tubulins or other dynein components to demonstrate proper localization to ciliary structures.

• Image acquisition: Capture images using confocal microscopy for optimal visualization of ciliary structures, which are often at the resolution limit of conventional microscopy.

What methods are recommended for co-immunoprecipitation studies involving DNAL1?

For co-immunoprecipitation of DNAL1 and its interacting partners:

• Sample preparation:

  • For axonemal extracts: Isolate tracheas from model organisms (e.g., rat), place in ice-cold saline, remove excess connective tissue, and prepare high-salt axonemal extracts .

  • For cell lines: Transfect cells (e.g., HEK293T) with tagged DNAL1 constructs (Myc-tagged DNAL1) for easier detection and pull-down .

• Co-incubation conditions: Incubate cell extracts containing DNAL1 (typically 72-500 μg protein) with axonemal extracts (approximately 230 μg) for 24 hours at 4°C to allow complex formation .

• Immunoprecipitation procedure: Use antibodies against the tag (e.g., anti-Myc) coupled to protein A/G beads for immunoprecipitation. Incubate the mixture overnight at 4°C with gentle rotation.

• Detection of interaction partners: Analyze immunoprecipitates by Western blot using antibodies against known or suspected interaction partners, such as dynein heavy chain (DNAH5) and α-tubulin .

• Controls: Include negative controls (non-specific IgG or untagged protein) and input controls (pre-immunoprecipitation samples) to validate specific interactions.

How can inconsistent results with DNAL1 antibodies be addressed in experimental settings?

When encountering inconsistent results with DNAL1 antibodies:

• Antibody validation reassessment: Verify antibody specificity through Western blot analysis of positive control samples (e.g., 3T3 cell lysate) alongside experimental samples .

• Sample preparation optimization:

  • For cell/tissue lysis: Ensure complete lysis using appropriate detergents and mechanical disruption methods.

  • For ciliary proteins: Consider specialized extraction methods for axonemal proteins, which may require high-salt conditions for efficient extraction .

• Epitope accessibility issues: If detecting DNAL1 in intact ciliary structures, ensure proper permeabilization. DNAL1's location within the axonemal complex may require more extensive permeabilization than standard protocols.

• Post-translational modifications: Consider that DNAL1 may undergo post-translational modifications that affect antibody recognition. The discrepancy between calculated (21.5 kDa) and observed (68 kDa) molecular weights suggests such modifications or tight complex association .

• Experimental conditions adjustment: Systematically optimize primary antibody concentration (typically 1-20 μg/mL depending on application), incubation time, and temperature based on signal-to-noise ratio .

What considerations are important when studying DNAL1 mutations in disease models?

When investigating DNAL1 mutations in disease contexts:

• Mutation characterization: Thoroughly characterize the specific mutation(s) under study, particularly those affecting conserved domains like the leucine-rich-repeat (LRR) consensus domain, which is critical for protein-protein interactions .

• Protein stability assessment: Evaluate stability of mutant proteins using cycloheximide chase or similar protein degradation assays. Certain mutations can significantly reduce DNAL1 half-life (e.g., 94% reduction at 6 hours compared to 30% for wild-type) .

• Interaction analysis: Assess how mutations affect binding to key partners like dynein heavy chain and tubulin using co-immunoprecipitation. Some mutations reduce these interactions by approximately 80% .

• Functional assays: Implement ciliary beat frequency analyses or flagellar motility assays to assess functional consequences of mutations on ciliary/flagellar dynamics.

• Model system selection: Choose appropriate model systems (primary ciliated cells, model organisms with ciliopathies) that accurately recapitulate the biological context in which DNAL1 functions.

What are the challenges in quantifying DNAL1 protein levels in different cellular contexts?

Accurate quantification of DNAL1 presents several challenges:

• Protein complex association: DNAL1 exists as part of large multiprotein complexes, which may affect extraction efficiency and antibody accessibility in different assays.

• Expression level variation: DNAL1 expression is highest in tissues with motile cilia or flagella (respiratory epithelium, testis), making detection in other tissues challenging and requiring careful assay optimization.

• Isoform-specific quantification: At least two isoforms of DNAL1 have been identified , necessitating careful antibody selection to detect the specific isoform(s) of interest.

• Western blot quantification: For accurate densitometric analysis, use appropriate loading controls (GAPDH, β-actin) and establish standard curves with recombinant DNAL1 when absolute quantification is needed .

• ELISA considerations: When using ELISA for DNAL1 quantification, validate the assay specifically for your sample type and ensure the antibody pair does not cross-react with other dynein light chains .

How should researchers design experiments to investigate DNAL1's role in Primary Ciliary Dyskinesia?

For investigating DNAL1's role in Primary Ciliary Dyskinesia (PCD):

• Patient sample analysis: Obtain nasal or bronchial biopsies from PCD patients and controls. Perform immunostaining with DNAL1 antibodies (typically at 2.5-20 μg/mL) to assess DNAL1 localization and abundance .

• Genetic analysis workflow:

  • Extract RNA from lymphoblastoid cells or relevant tissues

  • Reverse transcribe using SuperScript II Reverse Transcriptase Synthesis Kit or equivalent

  • Amplify DNAL1 cDNA in overlapping segments by PCR

  • Sequence PCR products directly on an ABI PRISM 3100 DNA Analyzer or similar system

• Mutation functional characterization: For identified mutations, create expression constructs (e.g., pc3myc plasmid) to produce normal and mutant DNAL1 proteins fused to epitope tags for comparative analysis .

• Protein stability assessment: Compare stability of mutant vs. wild-type DNAL1 using cycloheximide chase assays with densitometric quantification at multiple time points (0, 3, 6 hours) .

• Interaction analysis: Assess how PCD-associated mutations affect binding to key partners (dynein heavy chain, tubulin) using co-immunoprecipitation followed by Western blot analysis .

What methodological approaches are recommended for studying DNAL1's potential role in HIV infection?

To investigate DNAL1's identified role as an HIV dependency factor (HDF) :

• Expression modulation experiments:

  • Design siRNA or shRNA constructs targeting DNAL1 for knockdown studies

  • Create overexpression systems using epitope-tagged DNAL1 constructs

  • Validate expression changes by Western blot using anti-DNAL1 antibody at 1-2 μg/mL

• Infection assays: Compare HIV infectivity and replication in cells with normal vs. altered DNAL1 expression using standard virological techniques (p24 ELISA, reporter virus assays).

• Mechanism investigation:

  • Perform co-immunoprecipitation with DNAL1 antibodies to identify viral proteins that interact with DNAL1

  • Use confocal microscopy with DNAL1 antibodies (20 μg/mL) for immunofluorescence to assess co-localization with viral components

• Ciliary function assessment: Evaluate whether HIV-DNAL1 interactions affect ciliary function, which might contribute to respiratory complications in HIV infection, using ciliary beat frequency measurements.

• Therapeutic potential evaluation: Screen for compounds that can modulate DNAL1-HIV protein interactions without disrupting normal ciliary function, using high-throughput binding assays.

How can DNAL1 antibodies be used to identify subcellular localization changes in disease states?

For detecting disease-associated changes in DNAL1 localization:

• Comparative immunofluorescence analysis:

  • Prepare cells/tissues from healthy and disease models

  • Fix and permeabilize uniformly across samples

  • Stain with DNAL1 antibody at 20 μg/mL for immunofluorescence

  • Co-stain with markers for cilia (acetylated tubulin), basal bodies (γ-tubulin), and other relevant subcellular structures

  • Image using high-resolution confocal microscopy

• Quantitative colocalization analysis: Perform Pearson's or Mander's colocalization coefficient analysis between DNAL1 and standard ciliary markers to quantify changes in localization.

• Live-cell imaging considerations: For dynamic studies, consider creating fluorescently-tagged DNAL1 constructs, validating that tag position doesn't interfere with normal localization by comparison to antibody staining patterns.

• Biochemical fractionation: Complement imaging with subcellular fractionation followed by Western blot analysis using anti-DNAL1 antibody at 1-2 μg/mL to quantify DNAL1 distribution across cellular compartments .

• Super-resolution microscopy: For detailed localization within axonemal structures, employ super-resolution techniques like STORM or STED, which can resolve components within the 9+2 axonemal structure beyond the diffraction limit of conventional microscopy.